EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Ranolazine effectively improves clinical symptoms in patients with slow flow coronary arteries: a randomized, double-blind, placebo-controlled clinical trial

Bahram Shahri, Vahid Reza Askari, Lida Jarahi, Ali Shariatikia, Vafa Baradaran Rahimi

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-024-03746-9 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Bahram Shahri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Ranolazine, No-Reflow Phenomenon, Cardiovascular Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The coronary slow flow phenomenon (CSF) causes persistent chest pains that can affect patients' quality of life. We aimed to examine the ranolazine impacts on clinical symptoms in CSF patients. The present randomized, double-blind, placebo-controlled trial consisted of 44 patients with CSF. For two months, patients were randomized to receive ranolazine (500 mg/twice daily) or placebo plus optimal medications. EuroQol-visual analogic scale (VAS) and Seattle Angina Questionnaire (SAQ) were performed at baseline and after one and two months of treatment. At the beginning and after one month of treatment, no remarkable difference was assumed in the mean of EuroQol-VAS and all five SAQ parameters between the ranolazine and placebo groups. Additionally, the median of EuroQol-VAS (P < 0.001) and all five SAQ parameters, including physical limitation (P < 0.001), stability of angina (P < 0.001), frequency of angina (P < 0.001), treatment satisfaction (P = 0.003 and P < 0.001), and understanding of the disease (P < 0.001), has significantly propagated after two months of treatment in both ranolazine and placebo groups. Interestingly, following two months of treatment, the mean of EuroQol-VAS (P = 0.013), physical limitation (P = 0.041), stability of angina (P = 0.016), frequency of angina (P = 0.042), and treatment satisfaction (P = 0.037), in the ranolazine group has notably elevated comparatively to the placebo group. Our findings showed that ranolazine ameliorates clinical symptoms in CSF patients after two months of treatment. Therefore, ranolazine may be an appropriate candidate in CSF patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RanolazineNo-Reflow PhenomenonCardiovascular AgentsHumansDouble-Blind MethodMaleFemaleMiddle AgedAgedTreatment OutcomeQuality of LifeAngina Pectoris

Stichwörter der Autor:innen

Coronary slow flow phenomenonEuroQol-visual analogic scaleRanolazineSeattle Angina Questionnaire

Substanzen

RanolazineCardiovascular Agents

Autor:innen und Institutionen

  • Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Community Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. shariatika991@mums.ac.ir.
  • Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. baradaranrv@mums.ac.ir.

Zitieren

APA

Shahri, B., Askari, V. R., Jarahi, L., Shariatikia, A., & Baradaran Rahimi, V. (2025). Ranolazine effectively improves clinical symptoms in patients with slow flow coronary arteries: a randomized, double-blind, placebo-controlled clinical trial. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03746-9

Vancouver

Shahri B, Askari VR, Jarahi L, Shariatikia A, Baradaran Rahimi V. Ranolazine effectively improves clinical symptoms in patients with slow flow coronary arteries: a randomized, double-blind, placebo-controlled clinical trial. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03746-9

BibTeX
@article{Shahri2025,
  author = {Shahri, Bahram and Askari, Vahid Reza and Jarahi, Lida and Shariatikia, Ali and Baradaran Rahimi, Vafa},
  title = {Ranolazine effectively improves clinical symptoms in patients with slow flow coronary arteries: a randomized, double-blind, placebo-controlled clinical trial},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-024-03746-9}
}
Kostenlos starten →